JAC Advance Access originally published online on June 18, 2007
Journal of Antimicrobial Chemotherapy 2007 60(2):410-413; doi:10.1093/jac/dkm215
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 ß-lactamases
1 Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung, Kaohsiung 833, Taiwan 2 Department of Applied Microbiology, National Chiayi University, 300 University Road, Chiayi 600, Taiwan 3 Department of Clinical Pathology, Lin-Kou Medical Center, Chang Gung Memorial Hospital, 5 Fu-Hsin Street, Kweishan, Taoyuan 333, Taiwan 4 Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, 259 Wenhua 1st Road, Kweishan, Taoyuan 333, Taiwan
Received 10 April 2007; returned 13 April 2007; revised 22 May 2007; accepted 22 May 2007
* Corresponding author. Tel: +886-3-3281200, ext. 8363; Fax: +886-3-3971827; E-mail: sulh{at}adm.cgmh.org.tw
Objectives: The study aimed to characterize the genetic basis of flomoxef and collateral ertapenem resistance in a clinical isolate of extended-spectrum ß-lactamase-producing Klebsiella pneumoniae (ESBL-KP) after flomoxef exposure.
Methods: Four ESBL-KP isolates (Lkp11–14) were recovered sequentially from four episodes of bacteraemia in an elderly patient. Laboratory investigations included genotyping by PFGE, resistance gene analysis by PCR and sequencing, and outer membrane protein analysis by SDS–PAGE. Plasmid analysis by DNA–DNA hybridization, electroporation and conjugation was also performed.
Results: Lkp14 was recovered after 21 days of flomoxef therapy. It demonstrated an indistinguishable PFGE pattern when compared with those produced by Lkp11–13. However, resistance to both flomoxef and ertapenem emerged in Lkp14. Molecular characterization revealed that, in addition to the pre-existing ESBL production (CTX-M-3 and SHV-5) and OmpK35 deficiency found in Lkp11–13, Lkp14 had acquired an extra plasmid-mediated AmpC ß-lactamase gene (blaDHA-1) and failed to express OmpK36, because of insertional inactivation by an insertion sequence IS5. Other resistance mechanisms, such as production of carbapenem-hydrolysing enzymes or expression of chromosomal efflux, were apparently not involved. Conjugational transfer of the plasmid-mediated blaDHA-1 gene into Lkp11 resulted in a significant increase in the MICs of cephamycins and ß-lactamase inhibitors, but not in those of carbapenems.
Conclusions: Lkp14 was apparently derived from the previously flomoxef-susceptible isolates, Lkp11–13. After flomoxef exposure, the in vivo acquisition of the plasmid-mediated blaDHA-1 gene has led to flomoxef resistance in Lkp14, and the concomitant depletion of OmpK36 expression has resulted in a collateral effect of ertapenem resistance and diminished susceptibilities to imipenem and meropenem.
Keywords: outer membrane proteins , OMPs , antimicrobial resistance mechanisms , carbapenems
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Grobner, D. Linke, W. Schutz, C. Fladerer, J. Madlung, I. B. Autenrieth, W. Witte, and Y. Pfeifer Emergence of carbapenem-non-susceptible extended-spectrum {beta}-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany J. Med. Microbiol., July 1, 2009; 58(7): 912 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Girlich, L. Poirel, and P. Nordmann CTX-M Expression and Selection of Ertapenem Resistance in Klebsiella pneumoniae and Escherichia coli Antimicrob. Agents Chemother., February 1, 2009; 53(2): 832 - 834. [Abstract] [Full Text] [PDF]
|
|